Crossmark

Pneumococcal vaccine coverage among individuals aged 18 to 64 years old with underlying medical conditions in the UK: a retrospective database analysis

Crossref DOI link: https://doi.org/10.1186/s12889-020-09613-5

Published Online: 2020-10-21

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Matthews, Ian http://orcid.org/0000-0001-6175-6512
Lu, Xiaoyan

Xia, Qian

Black, Wynona

Nozad, Bayad
Funding

Funding for this research was provided by:

Merck Sharp and Dohme (N/A)
License Information

Text and Data Mining valid from 2020-10-21

Version of Record valid from 2020-10-21
More Information

Article History

Received: 4 December 2019

Accepted: 26 September 2020

First Online: 21 October 2020

Ethics approval and consent to participate

: The protocol for this study was approved by the CPRD Independent Scientific Advisory Committee (ISAC reference number 19_020R2).

: Not applicable.

: IM is an employee of Merck Sharp & Dohme Ltd., UK and owns shares in Merck & Co., Inc., Kenilworth, NJ, USA. WB is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. XL is a former employee of MSD France. QX is a former employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. BN is an Honorary Clinical Senior Lecturer, Department of Primary Care and Public Health, Imperial College London. He has received professional fees from Sanofi Pasteur MSD for attending advisory panels and other consultancy projects.

Document is current

Any future updates will be listed below